Introduction {#Sec1}
============

George Hoyt Whipple in 1907 explains Whipple's disease, as a multisystemic chronic infectious disease. He identified silver stained rod shaped bacterium in vacuoles associated with macrophages of patients, he initially did not think of them as the cause for the disease rather he think that intestinal lipodystrophy (Whipple's disease) was caused due to some novel disturbances in fat metabolic schemes (Whipple [@CR46]). When the first successful treatment started by using antibiotics in 1952, determined that this bacterium might be the major causative agent of this disease (Paulley [@CR33]). An electron microscopic study in 1960′s provided additional support for this hypothesis (Cohen et al. [@CR6]; Yardley and Hendrix [@CR48]). Whipple's disease occurs uncommonly, as a multisystemic disorder (inexact annual frequency less than 1 per 1,000,000 populace) that specially affects middle-aged Caucasian men (Fenollar et al. [@CR12]; Ramharter et al. [@CR36], Dobbins et al. [@CR9]). This bacterium was found to mostly affect small children (Keita et al. [@CR22]) and sewage workers (Schöniger-Hekele et al. [@CR41]). Since, its first portrayal by Whipple in very beginning of first decade in twentieth century (Whipple [@CR46]), a limited progresses with in pathogenesis, prognosis, and treatment of the malady have been made. The bacterium gets internalized in to lamina propria of intestine and then make its way to mucosal macrophages, as this bacterium induces the decreased expression of CD11b in such macrophages (CD11b on macrophages frequently mediates the intracellular degradation of bacteria) causes flip in the scenario (inappropriate antigen presentation by such macrophages and dendritic cells). This specially reasons the boom in IL-10, TGF-β and CCL-18 expression and decrease in IFN-γ, which in turn causes destroy in maturation of phagosomes and decrease in thioredoxin expression, lead them unable to kill bacterium and antigen presentation (Moss et al. [@CR29], [@CR30]).

An unseemly development of proficient antigen-presenting cells caused by the presence of interleukin 10 and interleukin 16, and the non appearance of interferon γ and interleukin 12 might lead to inadequate antigen-presentation and hinder the incitement of antigen-specific T-helper 1 cells enhancing growth and systemic spread of *Tropheryma whipple.* The nearby generation of provocative cytokines through macrophages and endothelial cells within the fringe might actuate lymphocyte invasion through a defective endothelial obstruction taken after by central aggravation, indeed in immunologically ensured tissues such as joints or the neuronal domain (Schneider et al. [@CR39]).Currently hydroxychloroquine (600 mg/day) and doxycycline (200 mg/day) used for treatment of whipple's disease for 12--18 months, but life time follow up is required (Lagier et al. [@CR25]), so it is time consuming treatment process and only few handful trials were conducted in earlier studies(Feurle et al. [@CR13]). Nowadays epitope based vaccines provide better options in search of good treatment strategy for such type of harmful and rare malady, even if the individuals are genetically predisposed as in case of classical Whipple's disease(Trotta et al. [@CR45]). This modern approach of putative vaccine determination which involves the use of proteomic databases is very handy and easy to use method not only for rare bacterial pathogens, but also very effective in case of harmful viruses like Nipah (Kaushik [@CR21]). *Tropheryma whipplei* was found to be associated with major ailments like gastroenteritis and endocarditis (Fenollar et al. [@CR11]).

In this research work, five proteins from proteomic data of *T. whipplei* were analyzed for allergenicity. Non-allergenic proteins were deployed for predicting epitopes. Predicted epitopes were subjected for immunogenic properties, structural modeling and the docking with corresponding MHC II alleles to investigate the strong binding affinity. Method is more economic, time efficient, and harmless when compared to the vaccine designing and testing in wet lab and animal testing strategies (Kumar et al. [@CR23]). Reverse vaccinology is the suitable approach as well as novel science method that use the genomic data with the utilization of computer for the arrangement of antibodies without culturing bacterium species (Kanampalliwar et al. [@CR20]; Tang et al. [@CR43]). It allow the choice in hands of human interface for selecting antigens from pathogenic set of DNA and most antigenic areas could be used to synthesize potential immunization to initiate defensive responses against such pathogenic species (Ada et al. [@CR1]). Epitopes based antibodies selection and production is explicitly less time consuming, economical and considered safest approach in vaccine designing. Earlier computational methods were found to be successful in analyzing genome and prediction of putative drugs for *T. whipplei* (Palanisamy [@CR32]), such studies provide motivation to craft vaccine targets by deploying in-silico approach*.* T-cell epitopes were screened out in this study may effectively elicit immune responses against this bacterium, and also similar type of recent study was found to be successful in determining epitope based vaccine agents for SARS-Cov2 (Joshi et al. [@CR19]). Brief flow chart of the study used to determine putative epitope based vaccine candidates against *T. whipplei* is presented in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Flow chart of the study used to determine putative epitope

Methodology {#Sec2}
===========

Retrieval of Proteins for *T. whipplei* {#Sec3}
---------------------------------------

Proteomes were retrieved in fasta format from NCBI-Genbank and UniProtKB databases. Five proteins of different functionality were selected with following accession no's: WP_042507409.1 DNA-directed RNA polymerase subunit beta (RPO-B), WP_033800049.1 co-chaperone GroES, WP_038104819.1 TerC/Alx family metal homeostasis membrane protein, WP_042505650.1 membrane protein insertase YidC, WP_042505746.1 murein biosynthesis integral membrane protein. This selection depicts the variability to include crucial proteins of pathogenic domain (Table[1](#Tab1){ref-type="table"}).Table 1Allergenicity results for analyzed proteins of *T. whipplei*S. noUniProtKB Accession No.GenBank Accession No.Allergen FP Score (Tanimoto similarity index)1Q76L83WP_042507409.10.85 NON ALLERGEN2Q96P47WP_033800049.10.81 NON ALLERGEN3P00846WP_038104819.10.91 NON ALLERGEN4O14569WP_042505650.10.83 NON ALLERGEN5Q7XBS0WP_011096746.10.89 NON ALLERGEN

Allergenicity Prediction for Proteins {#Sec4}
-------------------------------------

The protein sequences were then deployed for further analysis based on Allergen FP V 1.0 for predicting allergenicity (Dimitrov et al. [@CR8]).

T-Cell Epitope Prediction {#Sec5}
-------------------------

Net MHCII PAN 3.2 server is used to find and screen out HLA alleles which have good interaction with selected non-allergens of pathogenic origin (Jensen et al. [@CR18]). To bring higher confidence in selecting epitope, VaxiJen server is deployed to determine antigenicity with threshold ≥ 0.7 for selected rare bacterium (Doytchinova et al. [@CR10]). By subjecting proteomic sequences to Net MHCII PAN 3.2 server we obtained 1147 epitopes for WP_042507409.1, 90 epitopes for WP_033800049.1, 309 epitopes for WP_038104819.1, 302 epitopes for WP_042505650.1, and 510 epitopes for WP_011096746.1,this server was used because of its neural networking algorithm based approaches for fine predictions. 1-log50k (affinity score) ≤ 0.6 is used to screen out possible epitopes presented in Table [2](#Tab2){ref-type="table"}. These epitopes were further subjected for antigenicity analysis based on VaxiJen scores.Table 2List of predicted epitopes based on NetMHCII 3.2 server and VaxiJen score (threshold value of 0.7 and above was selected)Protein IDAllele\
(HLA)POSPeptide1-log50k(aff)VaxiJenAntigen/non antigenQ76L83DRB1_0101328IRYLAALHL0.5810.9461AntigenDRB1_0103328IRYLAALHL0.3110.9461AntigenDRB1_0301801LSAEERLLR0.2710.2947Non antigenDRB1_0401225FLRAIGMTD0.292− 0.3463Non antigenDRB1_0404328IRYLAALHL0.3750.9461AntigenDRB1_0405328IRYLAALHL0.3360.9461AntigenDRB1_0406328IRYLAALHL0.2550.9461AntigenDRB1_0701328IRYLAALHL0.4960.9461AntigenDRB1_0802324IIATIRYLA0.284− 0.5053Non antigenDRB1_11011010YMYVLKLHH0.4511.2693AntigenDRB1_1302154FVINGTERV0.445− 0.7514Non antigenQ96P47DRB1_010184YTILASRDV0.4100.2401Non antigenDRB1_040686ILASRDVLA0.200− 0.1277Non antigenP00846DRB1_0101222FFSLTGLRQ0.478− 0.0649Non antigenDRB1_0103244YMKFGVAAL0.1940.3077Non antigenDRB1_0301152GLLDKVMIR0.2490.6173Non antigenDRB1_0401198MFALDSIPA0.3430.4086Non antigenDRB1_0404295IIALSVALS0.3390.8054AntigenDRB1_0405222FFSLTGLRQ0.350− 0.0649Non antigenDRB1_0406295IIALSVALS0.2370.8054AntigenDRB1_070187FRFAVPEIF0.4201.2093AntigenDRB1_080218MLVTVRRPA0.314− 0.5928Non antigenDRB1_090187FRFAVPEIF0.4071.2093AntigenDRB1_0901244YMKFGVAAL0.3860.3077Non antigenDRB1_1001222FFSLTGLRQ0.477− 0.0649Non antigenDRB1_110118MLVTVRRPA0.402− 0.5928Non antigenDRB1_1302159IRMNVSKNY0.4200.7822AntigenDRB1_1602222FFSLTGLRQ0.335− 0.0649Non antigenO14569DRB1_0101175FYALQAGQA0.5390.6085Non antigenDRB1_0301278LAFELRRKR0.2200.7910AntigenDRB1_0401175FYALQAGQA0.2840.6085Non antigenDRB1_04048FLQNILLPI0.2990.1551Non antigenDRB1_04058FLQNILLPI0.3410.1551Non antigenDRB1_1001175FYALQAGQA0.4670.6085Non antigenDRB1_110163FLKQIRAQR0.438− 0.0522Non antigenDRB1_13028FLQNILLPI0.4780.1551Non antigenQ7XBS0DRB1_0101374YILQKAFYA0.5560.3071Non antigenDRB1_0103374YILQKAFYA0.2740.3071Non antigenDRB1_0401374YILQKAFYA0.3230.3071Non antigenDRB1_0404334VLMVSAFPL0.3501.2114AntigenDRB1_0405374YILQKAFYA0.3120.3071Non antigenDRB1_0406334VLMVSAFPL0.2501.2114AntigenDRB1_0701334VLMVSAFPL0.5391.2114AntigenDRB1_0802435FLAIRVKLG0.2741.1141AntigenDRB1_0901334VLMVSAFPL0.4361.2114AntigenDRB1_1001374YILQKAFYA0.4730.3071Non antigenDRB1_1101503YFLVITRCR0.416− 0.2632Non antigenDRB1_1302334VLMVSAFPL0.4121.2114AntigenDRB1_1602374VLMVSAFPL0.3660.3071Non antigen

Prediction of Epitope's Toxic Behavior {#Sec6}
--------------------------------------

Toxicity for putative peptides was designated by using SVM scores from Toxin Pred web server (Gupta et al. [@CR15]). Non toxic peptides were finalized for further analysis.

Molecular Structural Modeling for Epitopes and Probable HLA Alleles {#Sec7}
-------------------------------------------------------------------

The tertiary structure or 3D structure for epitope is determined by using PEP-FOLD 3 web server (Lamiable et al. [@CR26]; Shen et al. [@CR42]; Thévenet et al. [@CR44]). And predicted Human leukocyte antigen alleles 3D structure was obtained from RCSB PDB database (Berman et al. [@CR3]). Also Ramachandran plot analysis was conducted for verification of results by using Molprobity server (Williams et al. [@CR47]).

Epitopes 3D Interaction or Molecular Docking with HLA Alleles {#Sec8}
-------------------------------------------------------------

The docking experiments was conducted by using PatchDock tool (Schneidman-Duhovny et al. [@CR40]), The predicted docked models of putative epitope and HLA alleles was selected on the basis of score, which relies on highest geometric shape complementarities and Atomic contact energy (Zhang et al. [@CR49]). This allows the best selection of epitope and HLA allele interaction. This tool is easy to deploy for all life science domains.

Analysis of Population Coverage {#Sec9}
-------------------------------

Immune Epitope Database (IEDB) analysis Resource tool of population coverage was used to predict population coverage of the putative epitopes that are exhibiting interaction to HLA alleles and based on MHC-II restriction data (Bui et al. [@CR4]). MHCPred tool was deployed for quantitative prediction of selected epitopes interacting to major Histocompatibility complexes (Guan et al. [@CR14]).

Molecular Docking Simulations {#Sec10}
-----------------------------

Epitope-HLA allele docked sets were then used for simulation and dynamics analysis by deploying NAMD (Phillips et al. [@CR34]) associated with VMD (Visual Molecular Dynamics) tool (Humphrey et al. [@CR17]).

Results {#Sec11}
=======

Non-allergen Determination {#Sec12}
--------------------------

Total 5 protein sequences were analyzed for allergenicity and depicted as non-allergen in Table [1](#Tab1){ref-type="table"} by using AllergenFP tool.

T-Cell Epitope Prediction {#Sec13}
-------------------------

Net MHCII PAN 3.2 server is deployed to identify promiscuous epitopes and probable HLA alleles of MHC Class II that interacts together by analyzing their 1-log50k values and binding affinities, then the VaxiJen scores were used with threshold of ≥ 0.7 with all informative details are presented in Table [2](#Tab2){ref-type="table"}.

Molecular 3D Modeling of Epitopes and HLA Alleles {#Sec14}
-------------------------------------------------

3D structural models of selected epitopes were designed by using PEP-FOLD 3 web server and than most common HLA DRB1 proteins structural models were derived by using RCSB-PDB database. In Table [3](#Tab3){ref-type="table"} PDB Id along with HLA alleles is exhibited. Molprobity results of Ramachandran plot analysis results shows satisfactory structural prediction (\> 85% residues in favorable region) of epitopes that were finalized at last in Fig. [8](#Fig8){ref-type="fig"}.Table 3HLA template model based on Pdb Id derived for MHC Class II alleles structure from RCSB-PDBAllele nameTemplate structure (PDB ID)HLA-DRB1\*01_014AH2HLA-DRB1\*01_033PDOHLA-DRB1\*03_011A6AHLA-DRB1\*04_015LAXHLA-DRB1\*04_044IS6HLA-DRB1\*04_054IS6HLA-DRB1\*04_064IS6HLA-DRB1\*07_013C5JHLA-DRB1\*08_023PDOHLA-DRB1\*09_011BX2HLA-DRB1\*10_013PDOHLA-DRB1\*11_016CPLHLA-DRB1\*13_021FV1HLA-DRB1\*16_026CPO

Molecular Docking of Epitopes and HLA Alleles {#Sec15}
---------------------------------------------

PatchDock tool was deployed for interaction between selected structures of epitopes and HLA DRB1 proteins. Then interaction data produced by docked molecules include ACE (Atomic contact energy) and best model score that leads to the final selection in the way of prediction for each pair. In Table [4](#Tab4){ref-type="table"} the selected models and rejected models both were included to enhance the comparative analysis. The two selected epitopes were VLMVSAFPL and IRYLAALHL interacting with 4 and 6 HLA DRB1 alleles respectively. VLMVSAFPL epitope is a part of DNA-directed RNA polymerase subunit beta and IRYLAALHL epitope is a part of murein biosynthesis integral membrane protein of *T. whipplei* and are major identifiers of this bacterium. Figure [2](#Fig2){ref-type="fig"} clearly depicts the good interaction between epitopes and HLA Alleles in docked results. In Fig. [2](#Fig2){ref-type="fig"}a Docked result of IRYLAALHL with HLA-DRB1\* 01:01 exhibits perfect hydrogen bond due to presence of tyrosine residue in epitope at 3rd position, while most of the other non polar amino acids of this epitope are depicts vander waals interactions with in the HLA model and in Fig. [2](#Fig2){ref-type="fig"}c Docked result of VLMVSAFPL with HLA-DRB1\* 04:04 exhibits perfect hydrogen bond due to presence of serine residue in epitope at 5th position, while most of the other non polar amino acids of this epitope are depicts Vander waals interactions with in the HLA model. In Fig. [2](#Fig2){ref-type="fig"}b, d both RCSB-PDB structures for selected HLA DRB1 alleles (i.e. 4AH2 and 4IS6) with predicted peptide considered as reference structure (Schlundt et al. [@CR38]; Chen et al. [@CR5]). The reference docked peptides have great difference in amino acid sequence in comparison to our screened epitopes but exhibits some resemblance alike of our epitopes in interaction towards antigen binding pocket. Figure [3](#Fig3){ref-type="fig"}a, b represents the free undocked HLA-DRB1 receptors (4AH2, 4IS6 respectively), while Fig. [3](#Fig3){ref-type="fig"}c, d represents free unbound putative epitopes (IRYLAALHL, VLMVSAFPL respectively) and their side chains. Figure [4](#Fig4){ref-type="fig"} graphically represents the selected epitopes and HLA alleles of MHC II on the basis of ACE values.Table 4Molecular docking results of screened epitopes with HLA allelesAlleleEpitopeBinding scoreAceEpitope selectionDRB1_0101 (4AH2)IRYLAALHL7704− 367.28SelectedDRB1_0103 (3PDO)IRYLAALHL7452− 321.11SelectedDRB1_0404 (4IS6)IRYLAALHL8064− 353.51SelectedDRB1_0405 (4IS6)IRYLAALHL8064− 353.51SelectedDRB1_0406 (4IS6)IRYLAALHL8064− 353.51SelectedDRB1_0701 (3C5J)IRYLAALHL7544− 349.18SelectedDRB1_1101 (6CPL)YMYVLKLHH7880− 288.29RejectedDRB1_0404 (4IS6)IIALSVALS6562− 136.21RejectedDRB1_0406 (4IS6)IIALSVALS6562− 136.21RejectedDRB1_0701 (3C5J)FRFAVPEIF8260− 223.61RejectedDRB1_0901 (1BX2)FRFAVPEIF9042− 127.68RejectedDRB1_1302 (1FV1)IRMNVSKNY8564344.23RejectedDRB1_0301 (1A6A)LAFELRRKR7746− 93.04RejectedDRB1_0404 (4IS6)VLMVSAFPL6788− 443.31SelectedDRB1_0406 (4IS6)VLMVSAFPL6788− 443.31SelectedDRB1_0701 (3C5J)VLMVSAFPL6868− 226.35SelectedDRB1_0802 (3PDO)FLAIRVKLG7812− 298.60RejectedDRB1_0901 (1BX2)VLMVSAFPL7960− 297.99SelectedDRB1_1302 (1FV1)VLMVSAFPL8500104.94RejectedFig. 2**a** Docked result of IRYLAALHL with HLA-DRB1\* 01:01 exhibits perfect hydrogen bond due to presence of tyrosine residue in epitope at 3rd position, while most of the other non polar amino acids of this epitope are depicting Vander waals interactions with in the HLA model. **b** MKMRMATPLLMQAL interacting with HLA-DRB1\*01:01 (4AH2) structure considered as reference. **c** Docked result of VLMVSAFPL with HLA-DRB1\* 04:04 exhibits perfect hydrogen bond due to presence of serine residue in epitope at 5th position, while most of the other non polar amino acids of this epitope are depicting Vander waals interactions with in the HLA model. **d** RQLYPEWTEAQRL epitope interacting with HLA-DRB\* 04:04 (4IS6) structure considered as referenceFig. 3Free HLA-DRB1 receptors and putative epitopes structure: **a** 4AH2 **b** 4IS6 **c** IRYLAALHL **d** VLMVSAFPLFig. 4Graphical representation of atomic contact energy (ACE) for docked complexes of putative epitopes and HLA DRB 1 alleles

Toxicity, Half Life, and Stability Analysis of Putative Epitopes {#Sec16}
----------------------------------------------------------------

Predicted epitopes VLMVSAFPL and IRYLAALHL have VaxiJen scores 0.9461 and 1.2114 respectively, they are also of non toxic nature as per the study of Toxin Pred tool and its toxicity scores (SVM score) represented in Table [5](#Tab5){ref-type="table"}. In Table [6](#Tab6){ref-type="table"} quantitative estimation of best interaction of epitope with HLADRB1 alleles were achieved with upright IC~50~ values by using MHCPred tool, this allows confidence of prediction. Table [7](#Tab7){ref-type="table"} shows Half-life and instability index for putative epitopes by deploying ProtParam expasy tool.Table 5Toxicity scores for putative epitopesEpitopeNo. of HLA bindersToxicity scoreToxicityVLMVSAFPL4− 1.19Non toxinIRYLAALHL6− 0.61Non toxinTable 6MHCPRED results for interacting epitopes and HLA DRB1 allelesEpitopeHLA allele used in testPredicted -logIC~50~ (M)Predicted IC~50~ value (nM)Confidence of prediction (Max = 1)IRYLAALHL**DRB0101**8.5982.520.89IRYLAALHL**DRB0701**5.9351161.451.00VLMVSAFPL**DRB0701**5.9541111.731.00Only two alleles were present in this database for MHC II i.e. DRB0101and DRB0701Table 7ProtParam tool used for predicting biochemical parameters (GRAVY, half-life, and instability index)EpitopeTheoretical PIHalf life (for mammalian reticulocytes)Instability index\
(percentage)GRAVYIRYLAALHL8.7520 h0.51 (stable)1.167VLMVSAFPL5.49100 h30.29 (stable)2.233

Population Coverage Analysis of Epitopes {#Sec17}
----------------------------------------

VLMVSAFPL and IRYLAALHL manifest 28.82% and 37.06% elicitation of immune responsiveness by world population by availing IEDB tool. The epitopes VLMVSAFPL and IRYLAALHL shows greater effect in European population by 29.63% and 42.68% respectively, and correspondingly similar results with North American population coverage analysis. This indicates its greater relevance in treatment of Whipple's disease as it is mostly seen in Caucasoid population. In Figs. [5](#Fig5){ref-type="fig"} and [6](#Fig6){ref-type="fig"} it is clearly represented in a graphical representation.Fig. 5Graphical representation of Population coverage for VLMVSAFPLFig. 6Graphical representation of population coverage for IRYLAALHL

Molecular Dynamic Simulation Studies {#Sec18}
------------------------------------

NAMD was deployed for simulation studies on docked Epitope---HLA allele sets to obtain RMSD values. Maximum value of RMSD for VLMVSAFPL and IRYLAALHL epitopes were analyzed, this gives more confidentiality in selection of vaccine candidate against *Tropheryma whipplei*. Figures [7](#Fig7){ref-type="fig"} and [8](#Fig8){ref-type="fig"} shows RMSD plots that indicates clear picture of selection of these two epitopes.Fig. 7Graphical representation of RMSD values for epitope IRYLAALHLFig. 8Graphical representation of RMSD values for epitope VLMVSFAPL

Discussion {#Sec19}
==========

*Immuno-informatics* is the suitable approach as well as novel science method that use the proteomic data with the utilization of computer systems for predicting epitopes without culturing bacterium species (Kanampalliwar et al. [@CR20]; Tang et al. [@CR43]). It allow the choice in hands of human interface for selecting antigens from pathogenic set of DNA and most antigenic areas could be used to synthesize potential immunization to initiate defensive responses against harmful pathogenic species (Ada et al. [@CR1]). In-silico approach was earlier successful in case of *Staphylococcus aureus* (Delfani et al. [@CR7]), *Mycobacterium tuberculei* (Mustafa [@CR31]) and numerous bacterial species, but *T. whipplei* is still not fully explored in this domain. Current regimens include hydroxychloroquine and doxycycline for treatment of Whipple's disease for 12--18 months, but life time follow up is required (Lagier et al. [@CR25]), so it is time consuming treatment process and only few handful trials were conducted in earlier studies (Feurle et al. [@CR13]).

In present study we identified two possible epitopes that can interact with MHC-II alleles to elicit immune response on individuals namely VLMVSAFPL epitope (part of DNA-directed RNA polymerase subunit beta), and IRYLAALHL epitope (part of murein biosynthesis integral membrane protein). These epitopes exhibit better interaction with HLA DRB1 alleles, as confirmed by deploying Molecular-Docking and Molecular-Simulation studies (Adhikari et al. [@CR2]). Population coverage analysis was found to be satisfactory and in earlier studies it was used in strengthening vaccine prediction aspects (Misra et al. [@CR28]). Very similar studies were also conducted successfully for related bacterium *Mycobacterium avium* and found to be successful in predicting epitopes (Gurung et al. [@CR16]). The epitope VLMVSAFPL was found to interact with 4 HLA alleles of HLA-DRB1 domain (04:04, 04:06, 07:01, 09:01) with satisfactory ACE values (− 443.3, − 443.3, − 226.3, − 297.9 respectively); and the epitope IRYLAALHL found to interact with 6 alleles of HLA-DRB1 domain (01:01, 01:03, 04:04, 04:05, 04:06, 07:01) with satisfactory ACE values (− 367.2, − 321.1, − 353.5, − 353.5, − 353.5, − 349.1 respectively) in docking results similar type of methodology was seen in recent studies in screening epitopes for SARS-Cov-2 (Joshi et al. [@CR19]). Both selected epitopes exhibit structural integrity as possess less than 35% instability index score, and half life greater than 20 h for mammalian reticulocytes, this makes the screening criteria more reliable. Also, more than 85% residues of selected epitopes come under favorable region in Ramachandran plot analysis (Fig. [9](#Fig9){ref-type="fig"}). Still no one has used vaccine based treatments for Whipple's disease, as it is thought to be rare and possess reduced genome but considered one of the harmful pathogen of human **(**Raoult et al. [@CR37]; La Scola et al. [@CR24]; Marth et al. [@CR27]).The effectiveness of epitope based vaccines for treatment of endocarditis has already been claimed (Priyadarshini et al. [@CR35]). But in our study we found the short peptides that can easily be synthesized and deployed in developing immunity in Caucasian populations against Whipple's disease.Fig. 9Ramachandran plot for putative epitopes **a** IRYLAALHL **b** VLMVSAFPL

Conclusion {#Sec20}
==========

In this study we obtained VLMVSAFPL and IRYLAALHL as predicted epitopes for vaccine crafting. This novel approach in crafting vaccine based treatment of *T. whipplei* will open new doors in research for creating regimens to treat such harmful bacterium by developing adaptive immune response and eradicating it globally before any future escalations takes place. The predicted epitopes can be deployed in crafting vaccines against *T. whipplei* bacterium after Molecular-wet lab corroboration.
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